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Abstract: This review concerns the defi nitions and appropriate analytical 
characterisations of herbal reference standards within the framework of regulatory 
requirements. It describes currently applicable rules and regulations, as well as future 
issues relating to the European Pharmacopoeia and United States Pharmacopoeia. 
It provides an update on the use and availability of pharmacopoeial (EP and USP) 
herbal reference standards since our last review was published in 2009. The continuing 
challenges facing manufacturers, suppliers and analysts are discussed on the basis of 
exemplary reference substances for herbal products in medicinal and food products. 
The article also reviews the special aspects of Brazilian stipulations (Brazilian 
Pharmacopoeia, Anvisa) by comparison with European regulations.
The term herbal products as used throughout this article refers to herbal drugs, herbal 
preparations and fi nished herbal medicinal products unless a different meaning is obvious 
from the context. More specifi c terms are used where necessary.
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Introduction
 Safety assessments must be a major concern 
for all manufacturers and suppliers of botanicals and 
botanical preparations intended for use as ingredients in 
pharmaceuticals and food supplements; not only with 
respect to their sense of responsibility to the customers 
but also to ensure compliance with the stringent statutory 
requirements (Ruparel & Lockwood, 2011). Unlike 
chemically defi ned products, the constituents responsible 
for the therapeutic activity and effi cacy of most herbal 
products are only known to a certain extent, if at all. For 
this reason, the active substance in an herbal medicinal 
product or food/dietary supplement is always the herbal 
preparation in its entirety and complexity, e.g. in the form 
of an extract or plant powder. The selection of constituents, 
so-called phytochemical markers, that are suitable for 
control purposes for herbal products is therefore essential 
(Reif et al., 2004; Helliwell, 2006; Veit & Wissel, 2007).
 Herbal medicinal products have to meet many 
statutory requirements relating to their manufacture, 
constitution, testing, storage and distribution. This means 
that the reference substances used to calibrate and validate 
the testing methods that are applied within the framework 
of quality control have to comply with regulations as 
well. Active substances in an HMP must be declared and 
tested on the one hand, while comprehensive validation 
must ensure that the applied methods provide precise, 
reproducible and accurate results on the other. Analytical 
methods are always affected by numerous variables, such as 
the matrix, the reagents and material used, as well as light, 
temperature, equipment and the mode of operation. The 
requirements relating to safe herbal products, particularly 
with regard to the low active constituent content, constitute 
a hurdle that can frequently only be met with a great deal 
of effort and expense. This article therefore gives a brief 
summary of offi cial defi nitions, practical requirements 
and applications for herbal reference standards within the 
framework of regulatory stipulations. It also focuses on 
current and future developments within the EP and USP, as 
well as special aspects relating to Brazilian legislation (e.g. 
Anvisa regulations). It should be read in conjunction with 
our previous review on herbal reference standards, which 
already contained a description of the basic regulatory 
requirements and analytical defi nitions (Schwarz et al., 
2009). 
Defi nitions of reference standards
 Apart from the challenges of marker selection and 
method development for herbal preparations, appropriate 
characterisation of reference standards is absolutely 
essential (EMA, 2008; Sahoo et al., 2010). There are 
offi cial, often country-specifi c stipulations, which defi ne 
the requirements that must be met by a compound in order 
to qualify as a reference standard. Furthermore, the term 
"reference standard" is also used in the context of reference 
preparations and reference spectra within the European 
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Herbal Reference Standards: applications, definitions and regulatory 
requirements
Tina Zöllner and Michael Schwarz
Rev. Bras. Farmacogn. Braz. J. Pharmacogn. 23(1): Jan./Feb. 20132
Pharmacopoeia's scope of application (EDQM, 2012).
 European Pharmacopoeia Chemical Reference 
Substances (CRS) offered by the European Directorate 
on the Quality of Medicines & HealthCare (EDQM), 
are primary reference standards by definition. A primary 
standard is defined as being: "A standard shown to have 
suitable properties for the intended use, the demonstration 
of suitability being made without comparison to an 
existing standard." Establishment and qualification take 
place within the framework of an elaborate process, which 
frequently includes testing in several laboratories, as well 
as the performance of inter-laboratory tests. Secondary 
standards are derived by comparison with primary 
standards. The term "working standard" is used to describe 
secondary standards that serve as standards within the 
framework of routine analysis. They are derived from 
primary reference standards and are therefore equivalent 
to secondary reference standards. 
 United States Pharmacopoeia (USP) Standards 
have been established in accordance with an extensive 
protocol and released for use by the USP References 
Substance Expert Committee. The rulings of the USP 
are described in detail in Section <11> of the General 
Chapters (United States Pharmacopeial Convention 2012). 
A relatively new development is that substances that were 
previously labelled "Authentic Substances" (AS) by the 
USP, which are highly characterised but not required for 
use in a USP-NF monograph, are now distributed as "USP 
Reference Standards". Although this transition simplifies 
the official definition, it does not absolve the customer 
from his obligation to prove suitability. Attention must be 
also paid to the validity statement for a current lot because 
it may be used only for as long as it remains listed on the 
web site (www.usp.org). Similar batch validity statements 
for reference substances from the EP are available from 
the EDQM home page (www.edqm.org). The user assumes 
responsibility for ensuring the validity of a batch and 
receives a substance with a label providing information 
concerning the quality but no certificate of analysis. In 
contrast to these official reference standards, some well-
established and acknowledged suppliers offer marker 
compounds with comprehensive certificates of analysis, 
which may be used in the same way.
Analytical characterisation of reference standards
 The following requirements for the analytical 
characterisation of primary reference substances are 
defined by official guidelines, e.g. EU/ICH and FDA 
Guidelines (European Commission 1998; EMA 1995; 
2000a,b; FDA, 1999), the GLP Directive (European 
Parliament and the Council of the European Union 2004) 
and the International Pharmacopoeia (WHO) (WHO, 
1999). Generally speaking, compounds that are to be 
used as reference standards are characterised by means of 
identity testing and exactly defined purity testing to obtain 
a content assignment. (Belz et al., 2010; Schwarz et al., 
2009; Thorpe & Wadhwa, 2011)
Identity
 The identity of a substance is verified by means of 
appropriate chemical attributes such as structural formula, 
empirical formula and molecular weight. Mass spectra 
can be recorded to obtain information about the molecular 
weight of the reference substance and information relating 
to the empirical formula can be obtained by measuring high-
resolution spectra. Typical fragmentation patterns enable 
initial interpretations of the underlying structural units and 
the presence of certain substituents. Mass spectrometry 
alone is seldom sufficient complete determination of the 
structure. UV and IR spectra may be used in the same 
manner to obtain structural information about typical 
functional groups and basic structural elements, but these 
spectra must always be compared with a spectra library 
or combined with other identity tests. Nuclear magnetic 
resonance (NMR) spectroscopy therefore performs 
a central role in identity testing. Measurement and 
interpretation 1D and 2D NMR spectra offers a means of 
achieving nearly complete structural clarification without 
the need for comparison with reference spectra. Alternative 
X-ray structural analysis is also possible but is subject to 
limitations regarding substance amounts and crystallisation 
properties. Apart from the methods mentioned above, other 
means of verifying the structural identity of a primary 
reference standard include measurement of the melting 
point, determination of optical rotation values and/or the 
recording of CD spectra for compounds with chiral centres, 
as well as TLC and elemental analysis.
Purity
 A combination of various analytical techniques 
is required to determine the purity of a primary reference 
standard. Selective separating procedures - usually HPLC 
or GC, or less frequently electrophoretic CE - are used to 
determine organic impurities. Attention must be given to 
the selection of suitable detection method that ensures that 
certain impurities are not left unaccounted for. UV or diode 
array detectors combined with HPLC are representative of 
fairly universal and sensitive detection technologies, and 
light-scattering detection techniques may also be used to 
detect natural substances (e.g. saponins), which lack a 
pronounced UV chromophore. Flame-ionisation detectors 
(FID) are highly recommended for gas chromatography. 
Other universal techniques, such as refractive index 
detection (RID), should not be used for HPLC because 
of the lack of sensitivity required for precise, quantitative 
purity testing. To the same extent, thermal conductivity 
detectors (TCD) and more selective detectors, such as 
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ECD, NPD, FPD or AED, should not be used for GC for 
the same reason.
 Differences in the response factors of the 
substance and the impurities (which also vary according 
to the pertinent method of detection) exert a significant 
influence on the purity testing process. Elimination of this 
methodical error is unaffordable for natural substances, 
however, due to the complex composition which prevents 
the identification and quantification of all constituents. The 
area normalisation (100%) evaluation method is therefore 
adopted, which ensures that the purer the reference 
substance, the smaller the error. Furthermore, the error is 
reduced if it is assumed that most impurities, that are co-
extracted during the isolation procedure, are similar to the 
substance in terms of structure, e.g. as shown by their UV 
spectra.
 It is also necessary to determine the water content 
and residual solvent content, as well as any inorganic 
impurities that were used during the synthesis or extraction 
process, which have not been removed completely or, in 
some cases, are integral parts of the substance. The water 
content can be determined by means of Karl Fischer 
microtitration and the residual solvent content can be 
determined by means of headspace GC analysis, whereby 
both methods only consume relatively small amounts 
of the reference substance. Organic impurities may be 
determined by means of ICP-MS, AAS or various titration 
methods, such as argentometric titration, according to the 
type of impurity and all of these methods are characterised 
by the fact that they can be carried out on a micro scale. 
 There are special aspects of impurity detection, 
which may be encountered in the context of this process. 
Glycosidic compounds usually form hydrates containing 
at least one extra molecule of water, which can lead to 
significant water content values between 5 and 10 %. These 
should not be dried too harshly, however, because of their 
hygroscopic properties. Examples that demonstrate the 
problems associated with residual solvents are hypericin 
(Hypericum perforatum), which incorporates pyridine 
very well, anisatin (Illicium anisatum), which exhibits 
similar properties with respect to MTBE or diethyl ether, 
as does silybinin (Silybum marianum) with respect to 
isopropyl alcohol. Isolated natural substances are often 
found in their salt form because a counter-ion is needed 
for a structure-specific charge at the core molecule. Salts 
may also be present for stability reasons or to facilitate 
the handling of a compound. Ammonium salts, metal 
salts of glycyrrhizin, the chlorides of diverse alkaloids or 
anthocyanins/anthocyanidins are just a few examples. Exact 
determination of the inorganic impurities is absolutely 
essential because the actual content rarely corresponds 
to the stoichiometric ratio (calculated according to the 
empirical formula).
 It has recently become evident that a certificate 
of analysis alone is no longer considered to be an 
adequate means of verifying the quality of a reference 
substance used in method validation or quality control if 
it is included as part of a registration dossier for herbal 
medicinal products/food supplements submitted to the 
responsible authority with an application for marketing 
authorisation. The authorities are demanding raw data to 
support the analytical data on the certificate of analysis, 
e.g. NMR, MS or IR spectra as well as HPLC or GC 
chromatograms, to an increasing extent. These demands 
are not fully comprehensible as a demand for spectral 
raw data alone would imply that the registration dossier 
would not only need to be judged from a regulatory point 
of view, but would need to be seen through the eyes of 
an analytical chemist experienced in structure elucidation 
as well. These recent requests may possibly be regarded 
as a first step towards implementation of the requirements 
laid down by the German Federal Institute for Drugs 
and Medical Devices (Bundesinstitut für Arzneimittel 
und Medizinprodukte, BfArM) as early as 1996. The 
BfArM expects detailed evidence of the quality of the 
reference substance used by means of so-called primary 
standard documentation as part of the quality module of 
the marketing authorisation dossier. Such documentation 
comprises a description of the general properties of the 
reference substance (e.g. appearance, solubility, colour), a 
brief description of the production method (e.g. isolation 
from natural source, synthetic), raw data and a detailed 
interpretation of the spectroscopic and spectrometric 
data – 1H-NMR, 13C-NMR, MS, IR, UV spectra (e.g. 
NMR signal assignment, interpretation of MS data 
including fragmentation patterns, structural reasons for IR 
absorption bands), TLC chromatogram including method 
description, results of elemental analysis (CHNO) and the 
determined water, residual solvent and inorganic impurity 
content values, as well as descriptions of the applied GC 
or HPLC procedures with all relevant chromatograms 
and particularly including the pertinent validation data 
(precision, linearity, specificity and accuracy). Furthermore, 
the BfArM is demanding not just one, but also a second, 
complementary chromatographic separation technique to 
verify that the selected chromatographic system is capable 
of determining the purity of the reference substance 
under investigation. Although not stipulated in any 
pharmacopoeia or international guideline, these are ideally 
two completely different techniques (e.g. HPLC and GC 
where possible) or at least methods that differ in terms 
of the composition of the stationary phase (e.g. C8, C18) 
and the mobile phase (e.g. acetonitrile vs. methanol), as 
well as in the method of detection (e.g. different detection 
wavelengths when using UV detection) (Bundesinstitut für 
Arzneimittel und Medizinprodukte, 1996).
Content assignment
 When all of the purity tests have been completed 
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and the methods have been validated to an adequate extent 
(EMA, 1995), the content of the primary reference standard 
can be calculated according to the following formula: 
Assigned content = (100% - (water + residual solvent + 
inorganic impurities) x chromatographic/electrophoretic 
purity) (%). 
 Recent developments and an increasing number 
of successful applications have transformed what used to 
be a purely scientific method into an established approach: 
quantitative nuclear magnetic resonance spectroscopy 
qNMR (Pauli et al., 2005; 2008; Diehl et al., 2007). 
Although qNMR is also subject to certain limitations, 
it has been included in the methods of analysis section 
(chapter 01/2009:20233) of the European Pharmacopoeia 
(EDQM, 2012; Veit et al., 2008) and has now become an 
accepted content assignment method. However, the qNMR 
technique has not been described in any pharmacopoeial 
monographs for botanicals or botanical preparations to 
date.
Reference standards in practice
 Unlike primary reference standards, secondary 
standards (or working standards) must undergo initial 
testing according to their intended purpose. They must 
exhibit identical characteristics to the primary standard 
and traceability must be assured, whereas less pure 
compounds or extracts are frequently inadequate as 
secondary standards in practical applications. Furthermore, 
the terms "primary standard", "secondary standard" and 
"working standard" are not used uniformly in practice and 
are unfortunately used misleadingly on some occasions. 
According to the Section 5.12 of the EP (EDQM, 2012), 
the user must ensure that he has a substance at his disposal, 
which has been characterised to an adequate extent and is 
of a quality that can be assured by means of a re-testing 
programme: "A system is established and implemented 
to ensure the continued fitness-for-use of the reference 
standards. Normally, a re-test programme is applied, 
taking account of the known physico-chemical properties 
and stability data for the reference standard. Reference 
standards are periodically tested for stability during 
storage." This approach can eliminate the need to maintain 
more than one batch of a primary standard and avoid any 
misunderstandings.
 The EDQM and the USP Convention distribute 
pharmacopoeial primary reference standards (CRS, USP-
RS), which fulfil all the regulatory stipulations regarding 
EP and USP monographs (EDQM, 2012; United States 
Pharmacopeial Convention, 2012). In full consequence, 
this means that the standards can be used for their intended 
purpose but may not be suitable for any other purposes. 
"Where a reference standard is needed, it is an integral part 
of the pharmacopoeial monograph or the manufacturer’s 
specification. Where a European Pharmacopoeia reference 
standard is referred to in a monograph or general chapter, 
it represents the official standard that is alone authoritative 
in case of doubt or dispute." (EDQM, 2012 - Section 5.12) 
This specificity has been even officially recognised in the 
introduction of ISO Guide 34 (International Organization 
for Standardization, 2009). Any deviations regarding usage 
for other purposes than the one for which the standard has 
been established must therefore be documented and the 
user must fully demonstrate the suitability. Furthermore the 
predefinition "Any value assigned to a reference standard 
is valid for the intended use and not necessarily for other 
uses." causes the necessity to accomplish own analytical 
characterizations in this case. To the same extent, the 
USP states "The use of these materials is specified in the 
article’s monograph, and these materials generally are 
necessary for use in the Assay and/or the Identification 
tests. The suitability of a USP RS for uses outside those 
specified in a monograph is the responsibility of the user." 
(United States Pharmacopeial Convention, 2012, Section 
<11>) and of course, certified reference substances which 
are characterised completely in accordance with the 
regulatory requirements are frequently used for many other 
applications than those described in the pharmacopoeial 
monographs.
 During the latest 11th International Symposium 
on Pharmaceutical Reference Standards in Strasbourg 
in September 2012 some differences between EP und 
USP with respect to their self-understanding of their 
mission became obvious. While USP also provides 
several reference standards not used in any of the USP-
NF monographs, the EDQM clearly defines its mission as 
providing reference standards solely for the purpose that 
its user can make unequivocal fail or pass decisions for 
the product analyzed by applying exactly the procedure 
as described in the corresponding EP monograph. 
Consequently, the EDQM has decided not to disclose 
data on the uncertainty values of the assigned content of 
its reference standards. This strategy is also recognized 
in ISO 34: “The measurement uncertainty associated to 
the content value of Ph. Eur. CRS is not stated since it is 
considered to be negligible in relation to the defined limits 
of the method-specific assays for which they are used” 
(International Organisation for Standardization, 2009; 
section 5.17). The reason for that strategy being, that the 
EDQM does not want the user of its reference standards to 
use such uncertainty data to make a product pass a test by 
re-calculating the test result including the uncertainty data, 
although the test result itself is outside of the specifications 
set in the respective monograph. Instead, the uncertainty 
of the reference standard content is already being included 
in the specifications of each monograph. In contrast to 
this approach of the EDQM, USP has started to provide 
uncertainty information for a growing number of reference 
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standards. This EDQM strategy also has implications 
for the users who want to establish secondary standards 
derived from an official EDQM CRS. While this is still 
possible for secondary standards used in identification tests 
such as infrared spectroscopy or for peak identification 
in separation techniques, it is NOT possible any more to 
prepare secondary standards to be used for quantitative 
analysis from an official EDQM CRS. This is because 
there is no uncertainty associated with “identity”, but the 
uncertainty associated with “content” has to be included 
once a secondary standards for quantitative purposes is to 
be established. However, as this data is not available from 
the EDQM, such secondary standard cannot be directly 
derived by e.g. doing a peak area comparison to the CRS. 
Instead a user who wants to replace an EDQM CRS with an 
in-house standard would need to perform a complete mass 
balance analysis for his in-house standard as described 
previously in this publication (i.e. characterizing the in-
house standard as a primary reference substance). Then a 
sample would need to be analyzed using the official Ph. 
Eur. CRS and the own in-house reference substance, and 
results would have to be compared. Thus, instead of tracing 
back a secondary standards directly to an official CRS, the 
procedure now is a comparison of results obtained with 
the CRS and the in-house standard. The EDQM also has 
announced to communicate this procedure to producers 
of secondary reference standards and eventually also take 
legal action against producers claiming that their secondary 
standards are traceable to an EDQM CRS (Egloff, 2012).
 It is worth mentioning that herbal reference 
extracts are now being included in the European and 
United States Pharmacopoeias alongside pure reference 
substances, but this is a very controversial issue. Apart 
from the advantages – easy availability of larger quantities 
and the relatively low price compared with the price of 
an isolated pure substance – major problems are also 
encountered in the application of reference extracts. Many 
extracts are hygroscopic, requiring special conditions for 
packaging, handling and storage processes. Furthermore, 
the quantification of such complex mixtures, where 
batches can vary significantly with respect to their matrix 
components, requires methods with high chromatographic 
resolution and reproducibility. Finally, a reference extract 
is always a derived or secondary standard, which means 
that no other additional standards can be derived from 
it and the range of applications is very limited, usually 
restricted to just a single assay in an herbal monograph. 
One example is "valerian dry extract HRS" (corresponding 
monograph: valerian root 07/2010:0453), which is only 
used for sesquiterpene acid content calculation (sum of 
valerenic acid and acetoxyvalerenic acid), whereas reagent 
grade valerenic acids are necessary for identity testing. 
Apart from this, the EDQM guideline postulates that CRS 
extracts and drugs are also intended and suitable for single 
use only, alternative extracts are neither applicable nor 
allowed.
Regulatory stipulations
 Regulatory requirements for herbal medicinal 
products (HMP) are clearly regulated in the EU (Vlietinck 
et al., 2009), in the USA and in many other countries. Food 
supplements have not been defined to the same extent but 
are covered by food law within the EU (EFSA, 2009; 
EFSA Panel on Dietetic Products, Nutrition and Allergies 
(NDA), 2011) and by cGMP for dietary supplements in the 
USA since June 2007 (United States of America Congress, 
1994; FDA, 2012). In contrast to this, Brazil has only just 
begun to stipulate official regulations for herbal products 
used in medicinal products, dietary and food supplements. 
Hence the quality aspect has been brought up more in 
discussions in recent years and the quality of reference 
standards and the pertinent documentation will play an 
important role in this respect.
 All globally operating manufacturers of drugs and 
medicinal products are affected by the guidelines drawn 
up by WHO, ISO and NIST, as well as by monographs 
of such pharmacopoeias as the European or United States 
Pharmacopoeia, which define and provide general and 
plant-specific requirements for the quality and quality 
control of plant-based products. Some fundamental 
requirements for the establishment, documentation and 
use of reference standards regarding active pharmaceutical 
ingredients can be found in the Note for Guidance on 
Good Manufacturing Practice for Active Pharmaceutical 
Ingredients (EMA, 2000b). Although they are not legally 
binding, ISO Guides 30-35 (International Organisation 
for Standardization, 1997, 2000a,b, 2006, 2008, 2009) are 
more essential for reference standard users. ISO Guide 30, 
for example, which defines a certified reference material 
(CRM) as follows: "Reference material, accompanied by 
a certificate, one or more of whose property values are 
certified by a procedure which establishes its traceability 
to an accurate realization of the unit in which the property 
values are expressed, and for which each certified value 
is accompanied by an uncertainty at a stated level of 
confidence."
 Particularly important for manufacturers in 
the pharmaceutical sector, or third parties who establish 
standards themselves instead of using pharmacopoeial 
standards, is that each set of rules and standards (ISO 
Guides and EP) contains cross-references to the other 
one. Any deviations must be documented with evidence 
of their equivalence, even if parts of documents, such as 
Section 5.12 "Reference standards" of the EP only have 
a virtually binding effect within the pharmacopoeia's 
scope of application. Furthermore, "Reference standards 
are shown to be suitable for their intended purpose; 
they are not necessarily suitable for other purposes." 
is an important principle laid down in the EP. The CRS 
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standards fulfil these specifications in full consequence. 
Hence reference standards are an important tool to not 
only ensure analytical quality and method transfer but also 
to guarantee the safety of herbal products, including the 
raw material, extracts, pharmaceutical formulations and 
food or dietary supplements. 
Current issues of the EP and USP
 The ongoing development of new products, 
improvements in the field of analytical techniques and 
the official acknowledgement of such traditional medical 
concepts as TCM or Ayurvedic medicine leads to a 
continuous stream of new monographs drawn up by EP and 
USP committees. This means that the selection of plant-
based reference materials will continue to present a major 
challenge in the foreseeable future. Promising monographs 
on plants containing caffeine (maté, green tea, guarana), 
Crataegi folium cum flore, Echinaceae purpureae succus 
expressus, Passiflora, Primulae flos, Serratulae coronatae 
herba, Uncariae tomentosae cortex, Urticae radix, Vitis 
viniferae folium, Withania somnifera radix are still being 
investigated by the EDQM, as well as numerous TCM 
monographs. State-of-the-art analytical techniques still 
include qNMR. In addition photometric methods are being 
replaced by more specific HPLC with different detection 
modes (UV, ELSD etc.) to an increasing extent.
Overview of the current use of reference extracts, reference 
substances and reagents 
 A number of new reference substances and 
extracts have been introduced since the publication of our 
last review (Schwarz et al., 2009), which covered European 
Pharmacopoeia 6.3 and United States Pharmacopoeia 31-
NF 26, Second Supplement.
 Three new reference extracts have been 
introduced up to edition 7.5 of the EP: Actaea racemosa 
dry extract for system suitability in the monograph on 
Black Cohosh (2069), kudzuvine root dry extract in the 
monographs on Kudzuvine Root (2434) and Thomson 
Kudzuvine Root (2483) and saw palmetto extract in the 
monograph on Saw Palmetto Fruit (1848). An overview of 
all currently used reference extracts and their application 
in the European Pharmacopoeia is given in Chart 1. Each 
of these three newly introduced extracts is used in quite a 
different way. The 'Actaea racemosa dry extract for system 
suitability' is a tool for peak identification in the sample to 
be analysed and also acts as a system suitability test, as its 
name already suggests, with respect to a minimum peak-
to-valley ratio between certain peaks in the chromatogram. 
Kudzuvine root dry extract is used to both identify various 
isoflavonoids in the HPLC chromatogram and to quantify 
puerarin and total isoflavonoids calculated as puerarin in 
the two monographs mentioned above, but a puerarin R is 
used as a reference substance in thin-layer chromatography. 
While use of an extract for peak identification of several 
isoflavonoids, which are not commercially available as 
reference substances, seems to be an approach that is 
not only expedient but also very time and cost efficient, 
quantitation could also have been easily achieved by 
means of a reasonably priced puerarin CRS, particularly 
as reagent grade puerarin material is also needed for TLC 
identity testing. Furthermore, the puerarin peak in the 
chromatogram provided with the reference extract is not 
very well resolved. The saw palmetto extract serves various 
purposes: it is used to identify peaks within the framework 
of identity testing and the assay, and to check for a specific 
peak-to-valley ratio in the system suitability test. Lauric 
acid CRS and oleic acid CRS are then used for quantitation 
of saturated and unsaturated fatty acids. This saw palmetto 
reference extract constitutes a very good example of the 
way in which an extract can be used to identify a large 
number of signals in the chromatograms and considerably 
reduce the requisite number of reference standards at the 
same time. In previous versions of the saw palmetto fruit 
monograph, several reagent grade "reference standards" 
were used in the assay: caprice acid, caprice acid, laurel 
acid, linoleum acid, linolenic acid, oleic acid, palmitic acid 
and palmitoleic acid. These reagent grade materials are no 
longer required for the assay now that the reference extract 
has been introduced and lauric acid and oleic acid have 
been changed from reagent grade to CRS.
 Apart from the fatty acids mentioned above, 
berberine chloride and hydrastine hydrochloride have 
also been changed from reagent grade material into CRS 
for use in monographs on goldenseal rhizome (1831) 
and Hydrastis canadensis for homeopathic preparations 
(2500), thus further reducing the number of reagents used 
for assays in European Pharmacopoeia 7.5. Refer to Chart 
2 for a complete overview on remaining reagents used in 
assays, which hopefully will be replaced by CRS in the 
future.
 In addition to some reagent grade materials 
being replaced by reference substances, EP has also 
introduced some new CRS for application in assays of 
new monographs, i.e. astragaloside IV in Astragalus 
mongholicus root (2435), baicalin in Baical Skullcap root 
(2438), honokiol and magnolol in Magnolia officinalis bark 
(2567; only official from EP 7.6), imperatorin in Angelica 
dahurica root (2556), naringin in Draynria rhizome (2563), 
osthole in Angelica pubescens root (2557), rosmarinic acid 
in Melissa leaf (1447), Melissa leaf dry extract (2524) and 
Peppermint leaf dry extract (2382), and tetrandrine in 
Fourstamen Stephania root (2478). The already existing 
rutoside trihydrate is now also used in addition to the 
previous applications in Sophora flower bud (2427) and 
chlorogenic acid in Artichoke leaf dry extract (2389). A 
complete overview of the currently available European 
Pharmacopoeia CRS for herbal monographs is given in 
Chart 3.
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 The USP, on the other hand, has introduced nine 
new reference extracts and 28 new reference substances up 
to edition USP35 – NF 30, Second Supplement. Of these 
28 USP RS, 26 are pure compounds, and two are mixtures 
of oligomeric grape procyanidins. The newly introduced 
reference extracts are Andrographis, Ashwagandha, Bacopa, 
Boswellia serrata, Centella asiatica, Curcuminoids, 
Forskohlii, Garcinia hydroxycitrate, Guggul, Malabar-
Nut-Tree leaf, maritime pine and Phyllanthus amarus 
extract. This means that reference extracts are used for all 
of the monographs that were scheduled for introduction 
in the near future at the time of last review (Schwarz et 
Chart 1: CRS reference extracts in the European Pharmacopoeia (Issue 7.5).
CRS reference extract (EP) Monograph # Monograph Identity Assay
Senna extract 0206 
0207 
0208 
1261
Senna leaf 
Senna pods Alexandrian 
Senna pods Tinnevelly 
Senna leaf dry extract standardised
x 
x 
x 
x
Milk thistle standardised dry extract 1860 
2071
Milk-thistle fruit 
Milk thistle dry extract refined and 
standardised
x 
x
Valerian standardised dry extract 0453 
1898 
1899 
2400 
2526
Valerian root 
Valerian dry hydroalcoholic extract 
Valerian tincture 
Valerian dry aqueous extract 
Valerian root cut
x 
x 
x 
x 
x
Agnus castus fruit standardised dry 
extract
2147 Agnus castus fruit x
Ginkgo dry extract for peak 
identification
1827 Ginkgo dry extract refined and 
quantified
Peak ID only
Ginkgolic acids 1827 Ginkgo dry extract refined and 
quantified
x
St. John's wort standardised dry extract 1874 St. John’ s wort dry extract 
quantified
x
Bilberry dry extract 2394 Fresh bilberry fruit dry extract 
refined and standardised
x
Ivy leaf standardised tincture 2148 Ivy leaf x
Standardised artichoke leaf dry extract 2389 Artichoke leaf dry extract SST and peak ID only
Kudzuvine root dry extract 2434 
2483
Kudzuvine root 
Thomson kudzuvine root
x 
x
Actaea racemosa dry extract for system 
suitability HRS
2069 Black cohosh SST and peak ID only
Saw palmetto extract 1848 Saw palmetto fruit SST and peak ID only
Chart 2: Reagents used for assays in the European Pharmacopoeia (Issue 7.5).
Reagent R in EP Monograph # Monograph Method Required purity Remarks
11-keto-β-boswellic acid 2310 Indian frankincense HPLC 90 % (HPLC) Percentage purity taken 
into consideration
acetyl-11-keto-β-boswellic 
acid
2310 Indian frankincense HPLC 90 % (HPLC) Percentage purity taken 
into consideration
apigenin 7-glucoside 0404 Matricaria flower HPLC 95 % (HPLC) Percentage purity taken 
into consideration
asiaticoside 1498 Centella HPLC 97 % (HPLC) HPLC purity taken into 
consideration
cinchonine 0174 
1818
Cinchona bark 
Cinchona liquid extract 
standardised
Photometry -
eugenol 2094 Oriental cashew 
for homoeopathic 
preparations
Photometry -
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Chart 3: CRS reference substances in the European Pharmacopoeia (Issue 7.5).
ferulic acid 1419 Eleutherococcus HPLC 99 % (HPLC) Reagent used in spite 
of ferulic acid CRS 
being available
ginsenoside Rb1 1523 
2383
Ginseng 
Notoginseng root
HPLC 95 % (HPLC) HPLC purity taken into 
consideration
ginsenoside Rg1 1523 
2383
Ginseng 
Notoginseng root
HPLC 95 % (HPLC) HPLC purity taken into 
consideration
hederacoside C 2092 Hedera helix for 
homoeopathic 
preparations
HPLC 95 % (HPLC) Percentage purity taken 
into consideration
marrubiin 1835 White horehound HPLC 95 % (GC) Percentage purity taken 
into consideration
parthenolide 1516 Feverfew HPLC 90 % (HPLC) Purity not taken into 
consideration
quercetin dihydrate 1828 Ginkgo leaf HPLC 90 % (HPLC) Content calculation 
allows for percentage 
of anhydrous quercetin. 
Reagent used in spite 
of quercetin dihydrate 
CRS being available
quinine 0174 
1818
Cinchona bark 
Cinchona liquid extract 
standardised
Photometry -
sinensetin 1229 Java tea HPLC 95 % (HPLC) Purity not taken into 
consideration
CRS reference substance 
in EP Monograph # Monograph Identity Purity/Limit Assay
arbutin 1054 Bearberry leaf x
astragaloside IV 2435 Astragalus mongholicus root x
baicalin 2438 Baical skullcap root x
benzyl alcohol 1827 Ginkgo dry extract refined and quantified x
berberine chloride 1831 
2500
Goldenseal rhizome 
Hydrastis canadensis for homeopathic 
preparations
x 
x
boldine 1396 
1816
Boldo leaf 
Boldo leaf dry extract
x 
x
caffeine 1504 Cola x
capsaicin 1859 
2336 
2337
Capsicum 
Capsicum oleoresin refined and quantified 
Capsicum tincture standardised
x 
x 
x
x 
x 
x
cephaeline hydrochloride 0094 
1875 
0093 
1530
Ipecacuanha root 
Ipecacuanha liquid extract standardised 
Ipecacuanha prepared 
Ipecacuanha tincture standardised
x 
x 
x 
x
chlorogenic acid 1866 
2389 
1821 
1897 
1822 
1823 
1824
Artichoke leaf 
Artichoke leaf dry extract 
Narrow-leaved coneflower root 
Nettle leaf 
Pale coneflower root 
Purple coneflower herb 
Purple coneflower root
x 
 
x 
x 
x 
x 
x
x 
x 
x 
x 
x 
x 
x
coumarin 2120 Melilot x x
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cyanidin chloride 2394 Fresh bilberry fruit dry extract refined and 
standardised
x
digitoxin 0117 Digitalis leaf x
emetine hydrochloride 0094 
1875 
0093 
1530
Ipecacuanha root 
Ipecacuanha liquid extract standardised 
Ipecacuanha prepared 
Ipecacuanha tincture standardised
x 
x 
x 
x
ferulic acid 1834 Lemon verbena leaf x
foeniculin for peak 
identification
0804 Anise oil x
ginkgolic acids 1827 Ginkgo dry extract refined and quantified x
glycyrrhizate 
(monoammonium)
2378 
1536 
0277
Liquorice dry extract for flavouring 
purposes 
Liquorice ethanolic liquid extract 
standardised 
Liquorice root
x 
x 
x
harpagoside 1871 
1095
Devil's claw dry extract 
Devil's claw root
x 
x
honokiol* 2567 Magnolia officinalis bark x
hydrastine hydrochloride 1831 
2500
Goldenseal rhizome 
Hydrastis canadensis for homeopathic 
preparations
x 
x
imperatorin 2556 Angelica dahurica root x
lauric acid 1848 Saw palmetto fruit x
magnolol* 2567 Magnolia officinalis bark x
naringin 2563 Drynaria rhizome x
oleic acid 1848 Saw palmetto fruit x
oleuropein 1878 Olive leaf x
osthole 2557 Angelica pubescens root x
purpureaglycoside A 0117 Digitalis leaf x
purpureaglycoside B 0117 Digitalis leaf x
quercetin dihydrate 1827 Ginkgo dry extract refined and quantified x
rosmarinic acid 1447 
2524
Melissa leaf 
Melissa leaf dry extract
x 
x
ruscogenins 1847 Butcher's broom x x
rutoside trihydrate 2427 
2184 
1874
Sophora flower-bud 
Buckwheat herb 
St. John's wort dry extract quantified
x 
x 
x
salicin 1583 
2312
Willow bark 
Willow bark dry extract
x 
x
tetrandrine 2478 Fourstamen Stephania root x
verbenalin 1854 Verbena herb x
*from EP 7.6 only.
al., 2009), i.e. turmeric, soy and the monographs from 
ayurvedic medicine (Andrographis, Ashwagandha, 
Boswellia, Garcinia and Guggul). The USP uses these 
reference extracts exclusively in the chromatographic 
procedures involved in identity testing, peak identification 
and/or system suitability testing in line with its previous 
activities. Maritime pine bark extract is the only one that 
is also used in a photometric assay. Where one or more 
new pure reference substance(s) is/are introduced in a 
new USP monograph, such substances are also used in the 
quantitative assays. These include the following substances: 
3-acetyl-11-keto-β-boswellic acid for Boswellia serrata, 
andrographolide for Andrographis, asiaticoside for Centella 
asiatica, bacoside A3 for Bacopa, bisdemethoxycurcumin, 
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curcumin and demethoxycurcumin for turmeric, calcium 
hydroxycitrate for Garcinia, daidzein, daidzin, genistein, 
genistin, glycitein and glycitin for soy, eleutheroside E for 
Eleuthero, forskolin for Forskohlii, guggulsterone Z for 
Guggul, phyllanthin for Phyllanthus amarus, withanolide 
A and withanoside IV for Ashwagandha and vasicine for 
Malabar-Nut-Tree. A complete overview on currently 
available USP reference extracts and USP reference 
substances and their applications is given in Charts 4 and 5 
respectively.
Pyrrolizidine alkaloids and steviol glycosides: two 
prominent examples
 Pyrrolizidine alkaloids and steviol glycosides are 
two examples that demonstrate the ongoing challenges 
facing manufacturers and suppliers who produce 
and distribute herbal products that are subject to the 
requirements or national and international legislation.
 For some time, now, people have been aware 
that some foodstuffs, particularly including mixed 
Chart 4: CRS reference extracts in the US Pharmacopoeia (up to and including USP35-NF 30 through Second 
Supplement, official on December 1, 2012).
USP reference extract Dietary Supplements Monograph Identity Content
P. Andrographis extract Andrographis, P. Andrographis and P. Andrographis extract x x (peak ID)
P. Ashwagandha extract Ashwagandha root, P. Ashwagandha root, P. Ashwagandha root 
extract
x x (peak ID)
P. American ginseng extract American ginseng, capsules, Ttblets, P. american ginseng, P. 
american ginseng extract
x x
P. Asian ginseng xxtract American ginseng, capsules, tablets, Asian ginseng, Tablets, P. 
American ginseng, P. American ginseng extract, P. Asian ginseng, 
P. Asian ginseng extract
x x
P. Bacopa extract Bacopa, P. Bacopa, P. Bacopa extract x x (peak ID)
P. Bilberry extract* P. Bilberry extract x x (peak ID)
P. Black cohosh extract Black cohosh, fluid extract, tablets, P. black chosh, P. black 
cohosh extract
x x (peak ID)
Boswellia serrata extract Boswellia serrata, Boswellia serrata extract x x (peak ID)
P. Cat's Claw Extract Cat's claw, capsules, tablets, P. cat's claw, P. cat's claw extract x x (peak ID)
P. Centella asiatica extract Centella asiatica, P. C.asiatica, P. C. asiatica extract, C. asiatica 
triterpenes
x x (peak ID)
Curcuminoids Turmeric, P. turmeric, P. turmeric extract, curcuminoids, capsules, 
tablets
x x (system 
suitability)
P. Decaffeinated green tea 
extract*
P. decaffeinated green tea extract x x (peak ID)
P. Echinacea angustifolia 
extract
Echinacea angustifolia, P. E. angustifolia, P. E. angustifolia 
extract
x -
P. Echinacea pallida extract Echinacea pallida, P. E. pallida, P. E. pallida extract x -
P. Echinacea purpurea extract Echinacea purpurea aerial parts, root, P. E. purpurea, P. E 
purpurea extract
x -
P. Eleuthero extract Eleuthero, P. eleuthero, P. eleuthero extract x
P. Forskohlii extract Forskohlii, P. forskohlii, P. forskohlii extract x x (peak ID)
P. Garcinia hydroxycitrate 
extract
Garcinia cambogia, P. Garcinia cambogia, P. Garcinia 
hydroxycitrate extract, Garcinia indica, P. Garcinia indica 
- x (system 
suitability)
Purified guggul extract Guggul, purified guggul extract, native guggul extract, guggul 
tablets
x x (peak ID)
P. malabar-nut-tree, leaf 
extract
Malabar-nut-tree, leaf, P. malabar-nut-tree, leaf extract 
P. Malabar-nut-Tree, leaf
- 
x
x (peak ID) 
x (peak ID)
Maritime pine extract Maritime pine, maritime pine extract x x (photometric)
P. Milk thistle extract Milk thistle, capsules, tablets, P. milk thistle, P. milk thistle 
extract
x x (peak ID)
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P. Phyllanthus amarus extract Phyllanthus amarus, P. P. amarus x x (peak ID)
P. Red clover extract P. Red clover, P. red clover extract, red clover, tablets x x (peak ID)
P. St. John's Wort extract P. St. John's Wort, St. John's Wort 
P. St. John's Wort extract
- 
x
x (peak ID) 
x (peak ID)
Powered chaste tree extract Chaste tree, P. chaste tree, P. chaste tree extract x -
Pygeum extract Pygeum, capsules, extract x -
Tomato extract containing 
lycopene
Tomato extract containing lycopene - x
P.: Powdered
Chart 5: USP reference substances (USP 35-NF30 through second supplement).
USP reference substance Monograph Identity Purity/limit Content
3-acetyl-11-keto-β-
boswellic Acid
DS Boswellia serrata, B. serrata extract x - x
(S)-allyl-L-cysteine DS Garlic fluid extract x - x
andrographolide DS Andrographis, P. Andrographis, P. 
Andrographis extract 
x - x
actein DS Black Cohosh, fluid extract, tablets, P. Black 
Cohosh, P. Black Cohosh extract
x - x (system suitability)
agigenin DS Garlic, P. Garlic x - -
agnuside DS Chaste tree, P. Chaste tree 
DS P. Chaste tree extract
- - x
x - x
alliin DS Garlic, Garlic delayed-release tablets, P. Garlic, 
P. Garlic extract
x - x
apigenin DS P. Soy isoflavones extract, capsules, tablets - - x (internal standard)
apigenin-7-glucoside DS Chamomile - - x
asiaticoside DS Centella asiatica, P. C. asiatica, P. C. asiatica 
extract, C. asiatica triterpenes 
x - x
aspartic acid DS P. Stinging nettle, P. Stinging Nettle extracts, 
Stinging nettle
- - x
atropine sulphate USP Belladonna extract, Belladonna extract tablets, 
Belladonna leaf, Belladonna tincture
- - x
bacoside A3 DS Bacopa, P. Bacopa, P. Bacopa extract x - x
berberine chloride DS Goldenseal, P. Goldenseal, P. Goldenseal 
extract
x - x
bisdemethoxycurcumin DS Turmeric, P. Turmeric, P. Turmeric extract, 
curcuminoids capsules, tablets, curcuminoids
x (HPLC) - x
caffeine DS P. decaffeinated green tea extract - x -
calcium 
(-)-hydroxycitrate
DS Garcinia cambogia, P. G. cambogia, P. 
Garcinia hydroxycitrate extract, Garcinia indica, P. 
Garcinia indica 
x (HPLC) - x
capsaicin DS Ginger, tincture, P. Ginger 
DS Ginger capsules, USP capsicum oleoresin
- x x
- - x
casticin DS Chaste tree, P. Chaste tree, P. Chaste tree 
extract
x - x
(+)-catechin DS Grape seeds oligomeric proanthocyanidins x x x (system suitability)
chlorogenic acid DS Echinacea angustifolia, E. pallida, E. pupurea 
aerial parts, E. purpurea root, P. E. angustifolia, P. 
E. angustifolia extract, P. E. pallida, P. E. pallida 
extract, P. E. purpurea, P. E. purpurea extract,  
DS Ginkgo, P. Ginkgo Extract
- - x
x - -
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β-chlorogenin DS Garlic, P. Garlic x - -
citric acid DS Cranberry liquid formulation  
DS Garcinia cambogia, P. G. cambogia, P. 
Garcinia hydroxycitrate extract, G. indica, P. G. 
indica
x (HPLC) - x
- x -
curcumin DS Turmeric, P. Turmeric,  P. Turmeric extract, 
curcuminoids capsules, tablets, curcuminoids
x (HPLC) - x
cyanidin 3-O-glucoside DS P. Bilberry extract - - x
cyanidin chloride DS P. Bilberry extract - x -
daidzein DS P. Soy isoflavones extract, capsules, tablets x (HPLC) - x
daidzin DS P. Soy isoflavones extract, capsules, tablets x (HPLC) - x
demethoxycurcumin DS Turmeric, P. turmeric, P. turmeric extract, 
curcuminoids capsules, tablets, curcuminoids 
x (HPLC) - x
23-epi-26-deoxyactein DS Black Cohosh, fluid extract, tablets, P. Black 
Cohosh, P. Black Cohosh extract
x - x
dextrose DS Cranberry liquid formulation - - x
digitoxin USP P. Digitalis x - -
diosmin* DS Diosmin x (HPLC) x x
diosmin for system 
suitability*
DS Diosmin - - x (system suitability)
docosyl ferulate DS Pygeum capsules, Pygeum extract x (HPLC) - x
eleutheroside B DS Eleuthero, P. Eleuthero, P. Euthero extract x - x
eleutheroside E DS Eleuthero, P. Eleuthero, P. Eleuthero extract x - x
emetine hydrochloride UPS Ipecac oral solution, Ipecac, P. Ipecac - - x
(-)-epigallocatechin-3-O-
gallate
DS P. decaffeinated green tea extract x - x
escin DS Horse chestnut, P. Horse chestnut, P. Horse 
chestnut extract
x - x
formononetin DS P. Red clover, P. Red clover extract, Red clover, 
tablets
x (HPLC) - x
forskolin DS Forskohlii, P. Forskohlii, P. Forskohlii extract x - x
fructose DS Cranberry liquid formulation - - x
genistein DS P. Soy isoflavones extract, soy isoflavones 
capsules, tablets 
x (HPLC) - x
genistin DS P. Soy isoflavones extract, soy isoflavones 
capsules, tablets 
x (HPLC) - x
ginger constituent 
mix (6-gingerol and 
6-shogaol)
DS Ginger, capsules, tincture, P. Ginger - - x (system suitability)
Ginkgo terpene lactones DS Ginkgo, P. Ginkgo extract 
DS Ginkgo capsules, tablets
- - x
x (HPLC) - x
ginkgolic acids DS P. Ginkgo extract - x -
gitoxin USP P. Digitalis x - -
glutamic acid DS P. Stinging nettle, P. Stinging nettle extract, 
stinging nettle
- - x
gammy-glutamyl-(S)-
allyl-cysteine
DS Garlic, P. Garlic - - x
glycitein DS P. Soy isoflavones extract, soy isoflavones 
capsules, tablets 
x (HPLC) - x
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glycitin DS P. Soy isoflavones extract, soy isoflavones 
capsules, tablets 
x (HPLC) - x
glycyrrhizic acid DS Licorice, P. Licorice, P. Licorice Extract x - x
grape seed oligmeric 
proanthocyanidins
DS Grape seeds oligomeric proanthocyanidins - x -
purified grape 
seed oligmeric 
proanthocyanidins
DS Grape seeds oligomeric proanthocyanidins x - x
guggulsterone Z DS Guggul, purified Guggul extract, native Guggul 
extract, Guggul tablets
x (HPLC) - x
hexacosanol DS Saw palmetto capsules 
DS Saw palmetto extract
x - -
- - x
2E, 4E-hexadienoic acid 
isobutylamide
DS Echinacea angustifolia, E. pupurea aerial parts, 
root, P. E. angustifolia, P. E. angustifolia extract, P. 
E. purpurea, P. E. purpurea extract
- - x
hydrastine DS Goldenseal, P. Goldenseal, P. Goldenseal 
extract
x - x
hyperoside DS Hawthorn leaf with flowers, P. Hawthorn leaf 
with flowers, P. St. John's Wort, St. John's Wort
x - -
isopteropodine DS Cat's Claw, capsules, tablets, P. Cat's Claw, P. 
Cat's Claw extract
- - x
isorhamnetin DS Ginkgo 
DS P. Ginkgo extract, Ginkgo capsules, tablets
- - x
x (HPLC) - x
kaempferol
 
DS Ginkgo  
DS P. Ginkgo extract, Ginkgo capsules, tablets
- - x
x (HPLC) - x
levomenol DS Chamomile - - x
L-methionine DS Garlic, Garlic delayed-release tablets, P. Garlic, 
P. Garlic extract
x - -
lutein DS Lutein preparation x - x
lycopene DS Lycopene preparation 
DS Tomato extract containing lycopene
- - x
x - x
malic acid DS Cranberry liquid preparation x (HPLC) - x
methyl caprate, methyl 
caproate, methyl 
caprylate, methyl laurate, 
methyl linoleate, methyl 
linolenate, methyl 
myristate, methyl oleate, 
methyl palmitate, methyl 
palmitoleate, methyl 
stearate
DS P. Saw palmetto, Saw palmetto 
DS Saw palmetto capsules, extract
- - x
x - x
oxybenzone DS P. St. John's Wort, P. St. John's Wort extract, St. 
John's Wort
- - x
parthenolide DS Feverfew, P. Feverfew x - x
phyllanthin DS Phyllanthus amarus, P. P. amarus x - x
protocatechuic acid DS Maritime pine, Maritime pine extract - - -
quercetin DS Ginkgo, Hawthorn leaf with flowers, P. 
Hawthorn leaf with flowers
- - x
DS Ginkgo capsules, tablets, P. Ginkgo extract x (HPLC) - x
quinic acid DS Cranberry liquid formulation x (HPLC) - x
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reserpine USP P. Rauwolfia serpentina, R. serpentina, tablets - - x
rutin DS Feverfew, Ginkgo, P. Feverfew, P. Ginkgo 
extract
x - -
scopolamine 
hydrobromide
USP Belladonna extract, tablets, Belladonna leaf, 
tincture
- - x
scopoletin DS P. Stinging nettle, P. Stinging nettle extract, 
Stinging nettle
x - x
sennosides USP Senna leaf, pods - - x
silybin DS Milk Thistle, capsules, tablets, P. Milk Thistle, 
P. Milk Thistle extract
- - x
silydianin DS Milk Thistle, capsules, tablets, P. Milk Thistle, 
P. Milk Thistle extract
x - x
β-sitosterol DS P. Stinging nettle, P. Stinging nettle extract, 
Pygeum capsules, Pygeum extract, Stinging nettle 
DS Pygeum, Saw palmetto capsules 
DS Saw palmetto extract
x - -
x 
-
- 
-
- 
x
sorbitol DS Cranberry liquid formulation - x -
sucrose DS Cranberry liquid formulation - x -
withanolide A DS Ashwagandha root, P. Ashwagandha root, P. 
Ashwagandha root extract 
x - x
withanoside IV DS Ashwagandha root, P. Ashwagandha root, P. 
Ashwagandha root extract
x - x
valerenic acid DS P. Valerian, P. Valerian extract, Valerian, tablets x - x
vasicine DS Malabar-Nut-Tree teaf, P. Malabar-Nut-Tree 
leaf, P. Malabar-Nut-Tree, leaf extract
x - x
vitexin DS Hawthorn leaf with flowers, P. Hawthorn leaf 
with flowers
x - x
*will become official with USP35-NF 30 Second Supplement on December 1, 2012; DS: Dietary Supplements; P.: Powdered.
salads and animal feed may be contaminated with plant 
material containing pyrrolizidine alkaloids (Röder, 
1995). Pyrrolizidine alkaloids and their N-oxides have 
been predominantly found in Asteraceae (e.g. Senecio, 
familiarly known as ragwort), Boraginaceae and Fabaceae. 
They are produced by medicinal plants including comfrey 
(Symphytum officinale), butterbur (Petasites) and coltsfoot 
(Tussilago farfara), but may also be found in honey (main 
contributors are Echium, Senecio and Borago). Some 
of these compounds are hepatotoxic, mutagenic and/or 
carcinogenic e.g. echimidine, senecionine and senkirkine. 
The metabolised Pyrrolo-Pyrrolidine derivatives have 
an almost equivalent mode of action to genotoxic 
carcinogens, such as aflatoxins, but not all substances 
of this compound class exhibit the same toxicity. The 
"Scientific Opinion on Pyrrolizidine alkaloids in food and 
feed", which was published by the European Food Safety 
Authority, summarises the level of scientific knowledge 
regarding PA toxicity and possible resources (EFSA Panel 
on Contaminants in the Food Chain (CONTAM), 2011). 
Appropriate analytical methods should therefore be used 
to detect and quantify every single pyrrolizidine alkaloid. 
 Apart from these toxicological studies, the 
EDQM has not included a corresponding section to the 
EP chapter or updated a monograph, in spite of the fact 
that HMP are concerned. At the same time, the safety of 
herbal products can only be assured by the use of suitable 
reference substances as suggested by various guidance 
documents issued by the EMEA Herbal Medicinal Product 
Committee (HMPC) and the FDA (EMA, 2006a,b; FDA, 
2004). The so-called markers are defined as follows: 
"Markers are chemically defined constituents of an herbal 
substance which are of interest for control purposes…". 
The pertinent monographs of the European or other 
Pharmacopoeias, e.g. USP etc. define markers for many 
herbal drugs and drug preparations but do not discharge 
the manufacturers from their liability to inform themselves 
about up-to-the-minute news regarding product safety. 
The framework for selection, characterisation and use of 
marker substances in other areas, particularly including 
plant-based food products, such as functional food and 
food/dietary supplements, has not yet been defined to the 
same extent as for herbal medicinal products. 
 Plants with sweet and aromatic flavours have been 
used as ingredients in food and beverages for hundreds 
of years. Aztec Sweet Herb (Stevia rebaudiana) started 
its success in South America, the fruit of Luo Han Gou 
(Siraitia, Momordica grosvenori) is well-known in Asia, 
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not only as a sweetener but also as a TCM drug, and the 
Chinese Blackberry (Rubus chingii var. suavissimus) is an 
essential component for a variety of herbal teas in Europe. 
A warranty for the quality of appropriate preparations and 
food requires efficient analytical methods and a broad 
spectrum of reference substances (Hansen & De Olivieria, 
1993; Kedik et al., 2003). Steviol glycosides, such as 
stevioside and the rebaudiosides, are 300 times sweeter 
than saccharose, free of calories and have enormous 
potential for new product developments in the food 
and luxury food industries, but regulatory stipulations 
require efficient analytical methods and suitable reference 
substances here as well. Stevia leaves were not approved 
as a foodstuff within the European Union until recently. 
A WHO recommendation (WHO, 2009) regarding 
Stevia rebaudiana with its steviol glycosides and several 
toxicological studies were required in order to initiate the 
procedure for EU approval. A positive safety assessment of 
steviol glycosides from EFSA took place at the end of March 
2010 and constituted the basis for the approval procedures 
in all European countries (EFSA Panel on Food Additives 
and Nutrient Sources (ANS), 2010). The regulation now 
permits the sale and use of this natural sweetener and was 
published on November 12, 2011. The legislation became 
effective in December 2011 (European Commission, 
2011). An efficient analytical HPLC method is suggested 
and this should be used for content determination in order 
to comply with the new legal requirements (JECFA 2010). 
The single components (rebaudioside D, rebaudioside A, 
stevioside, rebaudioside F, rebaudioside C, dulcoside A, 
rubusoside, rebaudioside B and steviol bioside) can be 
determined easily using reference substances. Europe is 
now becoming an open market for stevia suppliers who 
offer this much anticipated ingredient.
Brazilian regulatory requirements
 In spite of Brazil being one of the ten largest 
pharmaceutical markets in the world and having the most 
diverse flora, few efforts have been made to enforce legal 
rules to ensure the efficacy, safety and consistent quality of 
phytotherapeutical products. In spite of their importance, 
around 70% of the phytopharmaceuticals have not been 
studied to a sufficient extent and the products have been 
marketed for many years without clear legal registration 
rules being imposed by the Brazilian government. 
Historical background
 In the 1930s, phytopharmaceuticals were 
declared to be pharmacopoeial preparations and, as such, 
exempted from legal registration. More astonishing was the 
misconception that "natural products are harmless to the 
health because they come from nature" resulting from drug 
registration and evaluation laws in the 1970s that not only 
confused pharmacopoeial substances with other substances, 
but also forgot to mention phytopharmaceuticals at all. 
Only one exception was made in 1991 as a consequence 
of its prohibition in Germany, which led to the product 
being banned from the Brazilian market as well (Petrovick 
et al., 1999): the plant Symphytum officinale, widely used 
for oral administration, contains the toxic pyrrolizidine 
alkaloids mentioned above. This unacceptable situation 
was improved by the Ministry of Health Ruling MS/
GM, which established guidelines for the National Health 
Surveillance System (SNVS) in 1994 on the basis of WHO 
recommendations (Piovesan & Labra, 2007; WHO, 1991; 
1995; World Health Organization Research Office for the 
Western Pacific 1993). A revised proposal was incorporated 
into directive n. 6, issued by SVS in 1995 to regulate the 
registration procedure for phytopharmaceutical products 
in Brazil (Petrovick et al., 1999). There are still many 
practical problems, however, that not only result from 
antiquated manufacturing processes, the limited number of 
research institutions for chemical, botanical, agronomic, 
pharmacological and toxicological studies and the frequent 
lack of motivation and financial opportunities on the 
part of the industry, but also from the ineffectiveness of 
government inspection agencies (Petrovick et al., 1999). 
The Brazilian Health Surveillance Agency (Anvisa) was 
established by Law 9782 in 1999 (Anvisa, 2012). This 
government regulatory agency is characterised by its 
administrative independence, financial autonomy and it 
is governed by the five members of its Collegiate Board 
of Directors. Anvisa's official mission is: "To protect 
and promote public health and to intervene in the risks 
caused by the production and use of products regulated by 
health surveillance. This mission must be carried out in 
coordination with states, municipalities and the Federal 
District, according to the Brazilian Unified Health System 
principles, in order to improve the quality of life of the 
population." Anvisa is not only responsible for registering 
drugs and issuing licenses to pharmaceutical laboratories; 
the agency also coordinates and controls activities 
relating to food registration, risk control and inspection. 
Furthermore (according to Law 9782/1999), Anvisa is 
responsible for coordinating health surveillance activities 
of laboratories that participate in the official health quality 
control laboratory network, which conducts analyses on 
products including herbal drugs, herbal medicinal products 
and foodstuffs. 
Current rules and regulations
 The following (Anvisa) recommendations apply 
to analytical validation and in cases where there are no 
standards for herbal medicines: "The best option to qualify 
an extract is the usage of isolated markers and/or typical 
chromatographic profiles." Qualified extracts can be used 
as working standards. Although primary standards in 
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accordance with the European Pharmacopoeia reference 
standard (CRS) or USP standard are accepted (RDC 
37/2001), RE899/2003 stipulates that laboratory standards 
with proven identity and purity may also be used where 
marker compounds are not laid down in the Brazilian 
Pharmacopoeia or any other legal stipulations. The Brazilian 
Pharmacopoeia defines a reference substance as a product, 
which is uniform in its properties, has an appropriate level 
of purity and in intended for use in assays where one or 
more of its attributes can be used for comparison with 
the examined sample. In general, the terms primary and 
secondary standard are used in the same way as defined 
for European Pharmacopoeia Chemical Reference 
Substances. The Brazilian law RDC 249/2005 (GMP) for 
intermediates and pharmaceutical raw materials, which 
will also apply to plant-based raw materials in the future, 
contains the following definitions: "Primary reference 
standard: A substance which high purity and authenticity 
was demonstrated by analytical testing. Secondary 
reference standard: A substance of established quality 
and purity as compared to a primary reference standard." 
RDC17/2010 is another important law (GMP), particularly 
with respect to finished products including herbal drugs. 
Section X describes best practice for the identification of 
plant drugs in the absence of pharmacopoeial monographs, 
as well as the quality control procedures to be adopted for 
raw materials and herbal medicines:
ART. 602. The reference standard may be a substance 
chemically defined (for example, a known active constituent 
or a marker substance or a class of chemical compounds 
present in herbal raw material) or a standard extract.
§1 reference standards officially approved by the Brazilian 
Pharmacopoeia or other codes authorized by the legislation 
in force, or else duly characterized reference standards.
§2 the Reference standard shall have the quality fit for this 
purpose. 
§3 All reference standards should be stored in appropriate 
conditions to avoid degradation. 
§4 for characterized reference standards, the full technical 
report of assessment must be submitted, including nuclear 
magnetic resonance, mass spectrometry (high resolution), 
infrared, melting point and/or HPLC (pureness based in 
the peak-related area).
§5 the standard abstract shall be mentioned in relation to 
a primary standard, in order to evidence its identity and 
the marker’s content .
 This shows that the Brazilian regulatory 
requirements for herbal products are specified to a 
much better extent today than they were as recently as 
twelve years ago. As a result, there is a growing need 
for appropriate characterised reference standards and 
validated analytical assays. The manufacturers and 
suppliers of herbal products are therefore being asked 
to not only improve their laboratory equipment but also 
expand their skills to include modern analytical techniques 
and reference substance establishment to meet all of the 
pertinent requirements. Helpful information can be found 
in recent publications, as well as statutory European 
recommendations, which often contain more stringent and 
more specific instructions. 
The Brazilian Pharmacopoeia
 The improvement of Brazilian laws and current 
activities of Anvisa regarding requirements for herbal 
products is reflected in the 5th edition of the Brazilian 
Pharmacopoeia (Anvisa, 2010). Like other Pharmacopoeias 
this Pharmaceutical Code official for Brazil establishes the 
minimum quality requirements for drugs, supplies, plants, 
medicines and health products. The first edition was 
published in 1929 and since then updated several times. 
For the first time, the 5th edition launched in December 
2010 will make previous editions invalid, which is already 
common practice for e.g. the European Pharmacopoeia. 
The current edition of the Brazilian Pharmacopoeia 
contains 592 monographs, 367 of which are part of the 
National List of Essential Medicines (Relação Nacional 
de Medicamentos Essenciais = RENAME). That list also 
currently contains a total of twelve herbal drugs (Ministério 
da Saúde, 2012). Regarding HMP the currently official 
Brazilian Pharmacopoeia contains around 60 monographs 
dealing with herbs, herbal tinctures, dry extracts and 
oils. In comparison to the 3rd and 4th edition the number 
of herbal monographs greatly increased from around 23 
to 45 and now to approximately 60. Beginning with the 
4th edition more and more medicinal plant monographs 
(e.g. for Brazilian herbs as guaraná, barbatimao, macela 
and espinheira-santa) were added or updated, respectively 
(Veiga-Jr & Mello, 2008). Furthermore the 4th edition 
adopted modern analytical methods and a chapter for 
pharmacognostical methods was included. In the 5th edition 
these parts were expanded. Also a significant number of 
titration assays were replaced by spectrophotometric and 
HPLC methods. Noteworthy is the newly introduced topic 
which deals with methods for preparation and analysis of 
herbal extracts considering also the nature of these extracts 
(e.g. fluid, soft or dry extracst). Six general methods 
regarding preparation and analysis of herbal extracts were 
added in the current edition (Pianetti, 2012). An overview 
on the current herbal monographs in the Brazilian 
Pharmacopoeia is given in Chart 6.
Conclusions
 Herbal medicinal products, as well as dietary and 
food supplements, have to comply with many statutory 
requirements relating to their manufacture, constitution, 
testing, storage and distribution. Within the framework of 
quality control, the use of appropriate reference standards 
or so-called phytochemical markers is essential to ensure 
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Chart 6: Herbal Monographs in the 5th edition of the Brazilian Pharmacopoeia.
Portuguese name Latin name Part used
Abacateiro Persea americana leaves
Alecrim Rosmarinus officinalis essential oil
Aloe Aloe vera leaves
Aloe Aloe ferox, A. africana, .A. spicata dry extract of the leaves
Alteia Althaea officinalis roots
Anis-doce Pimpinella anisum fruits
Anis-estrelado Illicium verum fruits
Arnica Arnica montana flowers
Bálsamo-do-peru Myroxylon balsamum balsam
Bálsamo-de-tolu Myroxylon balsamum balsam
Barbatimão Strypnodendron adstringens bark
Baunilha Vanilla planifolia fruits
Beladona Atropa belladonna leaves
Benjoim Styrax benzoin, St. paralleloneuron resin
Boldo Peumus boldus leaves; tincture of the leaves
Calêndula Calendula officinalis flowers
Canela-da-china Cinnamomum cassia bark
Canela-do-ceilão Cinnamomum verum bark
Capim-limão Cymbopogon citratus leaves
Cardamomo Elettaria cardamomum seeds
Carqueja Baccharis trimera herb
Castanha-da-india Aesculus hippocastanum seeds
Centela Centella asiatica leaves
Chapéu-de-couro Echinodorus grandiflorus leaves
Cratego Crataegus spp. leaves and flowers
Cúrcuma Curcuma longa rhizome
Endro Anethum graveolens fruits
Espinheira-santa Maytenus ilicifolia leaves
Estévia Stevia rebaudiana leaves
Estramônio Datura stramonium leaves
Genciana Gentiana lutea roots and rhizome
Guaraná Paullinia cupana seeds
Hamamelis Hamamelis virginiana tincture of the leaves
Hidraste Hydrastis canadensis roots
Hortelã-pimenta Mentha × piperita leaves; essential oil
Jaborandi tintura Pilocarpus microphyllus tincture leaves
Laranja-amarga Citrus aurantium exocarp
Maracujá-azedo Passiflora edulis leaves
Maracujá-doce Passiflora alata leaves
Meimendro Hyoscyamus niger leaves
Melissa Melissa officinalis leaves
Noz-de-cola Cola nitida seeds
Óleo de Amendoim Arachis hypogaea oil
Óleo de Gergelim Sesamum indicum oil
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that products are safe and efficacious. A great deal of 
effort and expense is needed to fulfil all of the official 
regulations relating to herbal products because of their 
complex matrices and often low active constituent content. 
It goes without saying that manufacturers and suppliers 
are under obligation to ensure that their products are 
safe, even in the absence of pharmacopoeial monographs. 
EU/ICH and FDA Guidelines, the GMP Directive as 
well as International Pharmacopoeias (WHO) define 
the analytical characterisation for compounds that are 
to be used as reference standards, especially for herbal 
medicinal products. The testing parameters must clearly 
prove identity and purity according to the purpose of the 
particular reference standard. Apart from CRS and USP 
primary reference standards, which fulfil the official 
specifications in full consequence, secondary standards 
and reference extracts are applied in appropriate manner. A 
continuous stream of new monographs included in the EP 
and USP demonstrates the need to lay down guidelines for 
a growing number of herbal products, including traditional 
medicines and TCM drugs, along with the need to update 
analytical methods. Current toxicological research (e.g. on 
pyrrolizidine alkaloids), which gives rise to new EMEA 
issues, must be taken into account to an adequate extent. 
Stevia products have also become the focus of attention as 
a result of new EU regulations last year. Although Brazil 
is one of the world's ten largest pharmaceutical markets 
and has the most diverse flora, regulatory stipulations were 
neglected to an alarming extent just a few years ago. A 
growing number of official rules and recommendations 
(Brazilian Pharmacopoeia, Anvisa regulations and Brazilian 
law) are now being drawn up for phytotherapeutical 
products to ensure that they are effective, safe and of 
a consistent quality standard. Provision of reference 
standards that are suitable for characterisation of herbal 
preparations with complex mixtures of active substances 
therefore continues to be an ongoing global challenge.
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